三例具有眼内表现的埃尔德海姆-切斯特病:罕见实体的影像学与组织病理学发现
本文为多中心回顾性观察性病例系列,报告3例经组织学确诊的埃尔德海姆-切斯特病(ECD)患者的眼内表现及多模态影像特征。眼内表现包括组织细胞性脉络膜浸润所致脉络膜病灶,并并发复发性浆液性视网膜脱离(SRD);抗血管内皮生长因子玻璃体内注射或维替泊芬光动力疗法联合全身化疗及口服糖皮质激素可短期缓解SRD,但复发常见。1例经脉络膜视网膜活检确诊,另1例携带新型ARAF阳性突变者经索拉非尼治疗后脉络膜病灶消退、SRD缓解。
要点
- ECD眼内表现罕见,多模态影像可见组织细胞性脉络膜浸润及复发性浆液性视网膜脱离。
- 抗血管内皮生长因子玻璃体内注射或维替泊芬光动力疗法联合全身化疗及口服糖皮质激素可短期缓解SRD,但复发常见。
- 1例经脉络膜视网膜活检确诊ECD,另1例携带新型ARAF阳性突变者经索拉非尼治疗后病灶消退。
核心结论
- 经组织病理学确认的ECD罕见眼内表现可通过多模态影像进行成像观察。
- 本文报告3例,其中1例经脉络膜视网膜活检组织学确诊,另1例携带新型ARAF突变并对索拉非尼靶向治疗有反应。
- 发现与ECD相关的新型体细胞突变使新型靶向全身药物得以应用,多模态影像可用于监测治疗反应。
研究设计与样本
- 多中心回顾性观察性病例系列,纳入3例经组织学确诊ECD并显示眼内表现的患者,在基线和随访时进行影像学检查。
主要发现
- ECD眼内表现在多模态影像上包括组织细胞性脉络膜浸润所致脉络膜病灶,并并发复发性浆液性视网膜脱离(SRD)。
- 采用抗血管内皮生长因子玻璃体内注射或维替泊芬光动力疗法联合全身化疗及口服糖皮质激素等眼部治疗后,观察到SRD短期缓解,但复发常见。
- 1例经脉络膜视网膜活检确诊ECD,可见组织细胞浸润、纤维化及特征性免疫组化染色。
- 另1例携带新型ARAF阳性突变,经索拉非尼治疗后多模态影像显示脉络膜病灶消退及SRD缓解,这些病灶此前对其他治疗形式耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report intraocular manifestations of Erdheim-Chester Disease (ECD) with multimodal imaging. DESIGN: A retrospective observational case series. METHODS: This was a multicenter case series of 3 patients with confirmed tissue diagnosis of ECD that showed intraocular manifestations and were imaged at baseline and follow-up visits. RESULTS: Intraocular manifestations are rarely observed in association with ECD. Intraocular manifestations of ECD seen on multimodal imaging include histiocytic choroidal infiltration causing choroidal lesions, complicated by recurrent serous retinal detachment (SRD). Short-term resolution of SRD was observed with ocular therapies including intravitreal injections of anti-vascular endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common. Chorioretinal biopsy confirmed the diagnosis of ECD in 1 case, with the presence of histiocytic infiltration, fibrosis, and characteristic immunohistologic staining. In another case, with a novel ARAF positive mutation, treatment with sorafenib showed regression of the choroidal lesions and resolution of the SRD on multimodal imaging. These lesions were previously resistant to other forms of therapy. CONCLUSIONS: Rare intraocular manifestations of ECD confirmed on histopathology can be imaged with multimodal imaging. We report 3 cases, including 1 case diagnosed through histology from chorioretinal biopsy and another case associated with a novel ARAF mutation responsive to targeted therapy with sorafenib. The identification of novel somatic mutation associated with ECD enabled treatment with a new-targeted systemic agent. Multimodal imaging in these cases can also be used to monitor response to therapy.
引用
- Tan ACS, Yzer S, Atebara N, et al. Three Cases of Erdheim-Chester Disease With Intraocular Manifestations: Imaging and Histopathology Findings of a Rare Entity. Am J Ophthalmol. 2017. PMID: 28153505. doi:10.1016/j.ajo.2017.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。